Approved For Marketing EXPANDED_ACCESS NCT04256265

An Expanded Access Program for Risdiplam in Participants With Spinal Muscular Atrophy (SMA)

An Expanded Access Program for Risdiplam in Patients With Type 1 or Type 2 Spinal Muscular Atrophy

Sponsor: Genentech, Inc.

Interventions Risdiplam

Updated 10 times since 2020 Last updated: Sep 30, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Muscular Atrophy, Spinal and is currently ongoing. Genentech, Inc. leads this study, which shows 10 recorded versions since 2026 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Approved For Marketing
Sep 2024 — Sep 2025 [monthly]

Approved For Marketing
Jul 2024 — Sep 2024 [monthly]

Approved For Marketing
Jan 2021 — Jul 2024 [monthly]

Approved For Marketing
Oct 2020 — Jan 2021 [monthly]

Approved For Marketing

Status: Available → Approved For Marketing

▶ Show 5 earlier versions

Sep 2020 — Oct 2020 [monthly]

Available
Jul 2020 — Sep 2020 [monthly]

Available
May 2020 — Jul 2020 [monthly]

Available
Apr 2020 — May 2020 [monthly]

Available
Mar 2020 — Apr 2020 [monthly]

Available

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genentech, Inc.

Data source: Genentech, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Atlanta, United States , Aurora, United States , Boston, United States , Charlottesville, United States , Chicago, United States , Columbus, United States , Grand Rapids, United States , Indianapolis, United States , Iowa City, United States and 18 more locations